Showing 1931-1940 of 2123 results for "".
- New Guideline Provides Clinical Recommendations for Excessive Daytime Sleepinesshttps://practicalneurology.com/news/new-guideline-provides-clinical-recommendations-for-excessive-daytime-sleepiness/2469682/Clinical practice guidelines for the treatment of central disorders of hypersomnolence have been updated by the American Academy of Sleep Medicine (AASM), for the first time since 2007, with new recommendations. The guideline is available online in the Journal of Clinical Sleep Medicine and provi
- Game-Based Digital Therapy for Individuals With Multiple Sclerosis Reduces Anxietyhttps://practicalneurology.com/news/game-based-digital-therapy-for-individuals-with-multiple-sclerosis-reduces-anxiety/2469670/Use of a game-based digital therapy (Personal Zen; Wise Therapeutics, New York, NY) reduced symptoms of anxiety in individuals with multiple sclerosis (MS). The digital therapy requires a prescription and uses adaptive, personalized gameplay to address mental health needs, and can serve as an at-
- Survey for Chronic Inflammatory Demyelinating Polyneuropathy Shows High Rate of Misdiagnosis and Strong Treatment Responsehttps://practicalneurology.com/news/survey-for-chronic-inflammatory-demyelinating-polyneuropathy-shows-high-rate-of-misdiagnosis-and-strong-treatment-response/2469664/A survey of individuals with chronic inflammatory demyelinating polyneuropathy (CIDP) showed high rates of misdiagnosis but also good response to treatment. According to the results, 70% of respondents were diagnosed at age 41 to 65, and more than 54% stated it took more than a year to be correct
- FDA Approves Avalglucosidase Alfa for Pompe Diseasehttps://practicalneurology.com/news/fda-approves-avalglucosidase-alfa-for-pompe-disease/2469662/The Food and Drug Administration (FDA) approved avalglucosidase alfa (avalGA) (Nexviazyme; Sanofi, Bridgewater, NJ) for the treatment of individuals age 1 year and up with late-onset Pompe disease (LOPD). Treatment of people with LOPD with avalGA improved respiratory function and timed walk
- Clinical Trials of Vidofludimus for Relapsing and Progressive Multiple Sclerosis Get Green Lighthttps://practicalneurology.com/news/clinical-trials-of-vidofludimus-for-relapsing-and-progressive-multiple-sclerosis-get-green-light/2469628/The Food and Drug Administration (FDA) cleared phase 3 ENSURE (NCT identifier not yet available) and phase 2 CALLIPER (NCT identifier not yet available) clinical trials of vidofludimus calcium (VFC)(IMU-83
- FDA Grants Orphan Drug Exclusivity for Mixed Salts Oxybate for Cataplexy or Excessive Daytime Sleepinesshttps://practicalneurology.com/news/fda-grants-orphan-drug-exclusivity-for-mixed-salts-oxybate-for-cataplexy-or-excessive-daytime-sleepiness/2469624/The Food and Drug Administration has granted 7 years of Orphan Drug Exclusivity for mixed salts oxybate (Xywav; Jazz Pharmaceuticals, Philadelphia, PA) for the treatment of cataplexy or excessive daytime sleepiness (EDS) caused by narcolepsy in individuals age 7 years or more. FDA
- Ublituximab Reduced Annualized Relapse Rate and Disability Progression in Multiple Sclerosishttps://practicalneurology.com/news/ublituximab-reduced-annualized-relapse-rate-and-disability-progression-in-multiple-sclerosis/2469621/In the phase 3 ULTIMATE trials (NCT03277261 and NCT03277248), ublituximab (UTX)(TG Therapeutics, New York, NY) decreased (ARR) and disability progression of relapsing multiple
- Nusinersen Treatment of Spinal Muscular Atrophy Provides Continued Motor Development and Studies Will Evaluate a Higher Dosehttps://practicalneurology.com/news/nusinersen-treatment-of-spinal-muscular-atrophy-provides-continued-motor-development-and-studies-will-evaluate-a-higher-dose/2469614/Continued development and studies of nusinersen (Spinraza; Biogen, Cambridge, MA), the first of several treatments for spinal muscular atrophy (SMA) developed in just the last 5 years, show sustained survival and improvement in motor function. Studies also suggest a higher dose may be more effect
- Diagnostic Kit Provides Accurate Spinal Muscular Atrophy Copy Number and Diagnosishttps://practicalneurology.com/news/diagnostic-kit-provides-accurate-spinal-muscular-atrophy-copy-number-and-diagnosis/2469589/A study published in The Journal of Molecular Diagnostics, showed an in vitro diagnostic kit (AmplideX Kit; Bio-Techne Corporation, Minneapolis, MN) has accuracy for timely results of carrier identification or diagnosis of spinal muscular atrophy (SMA). In the study, the single-tu
- Increased Risk of Dementia Correlates With Decreased Kidney Functionhttps://practicalneurology.com/news/increased-risk-of-dementia-correlates-with-decreased-kidney-function/2469588/In a registry-based study published in Neurology, individuals with reduced kidney function had increased risk of dementia development. In the study, there were cases of dementia per 1,000 person-years in individuals with a normal kidney filtration rate of 90 to 104 mL per minute and with severe k